Impact of atherosclerosis on the relationship between glycemic control and mortality in diabetic patients on hemodialysis

Clinical Nephrology

Volumn 78, Issue 4, 2012, Pages 273-280

  Inaba, Masaaki ^a   Maekawa, Kiyoshi ^b   Okuno, Senji ^b   Imanishi, Yasuo ^a   Hayashino, Yasuaki ^c   Emoto, Masanori ^a   Shoji, Tetsuo ^a   Ishimura, Eiji ^a   Yamakawa, Tomoyuki ^b   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Cardiovascular disease; Glycoalbumin; Hemodialysis; Mortality

Indexed keywords

C REACTIVE PROTEIN; GLYCOSYLATED ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BODY MASS; COHORT ANALYSIS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; GLYCEMIC INDEX; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; SMOKING HABIT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84867669334     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106940     Document Type: Article

References (39)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28: 103-117.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
4. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J M. e.d. 2003; 348: 383-393.
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOPNIDDM trial. JAMA. 2003; 290: 486-494.
6. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth SDiabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003; 348: 2294-2303.
7. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005; 165: 2659-2665.
8. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005; 352: 2049-2060.
9. Shoji T, Emoto M, Tabata T, Kimoto E, Shinohara K, Maekawa K, Kawagishi T, Tahara H, Ishimura E, Nishizawa Y. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 2002; 61: 2187-2192.
10. Shinohara K, Shoji T, Tsujimoto Y, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y. Arterial stiffness in predialysis patients with uremia. Kidney Int. 2004; 65: 936-943.
11. Kimoto E, Shoji T, Shinohara K, Hatsuda S, Mori K, Fukumoto S, Koyama H, Emoto M, Okuno Y, Nishizawa Y. Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2245-2252.
12. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol. 2001; 12: 2117-2124.
13. Nishizawa Y, Shoji T, Maekawa K, Nagasue K, Okuno S, Kim M, Emoto M, Ishimura E, Nakatani T, Miki T, Inaba M. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2003; 41 (Suppl 1): S76-S79.
14. Kawagishi T, Nishizawa Y, Konishi T, Kawasaki K, Emoto M, Shoji T, Tabata T, Inoue T, Morii H. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int. 1995; 48: 820-826.
15. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM. Aortic and large artery compliance in end-stage renal failure. Kidney Int. 1990; 37: 137-142.
16. Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant. 1997; 12: 718-723.
17. Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, Saito S. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examina tion. J Am Soc Nephrol. 2005; 16: 1141-1148.
18. Hase H, Tsunoda T, Tanaka Y, Takahashi Y, Imamura Y, Ishikawa H, Inishi Y, Joki N. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int. 2006; 70: 1142-1148.
19. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001; 24: 909-913.
20. Medina RA, Pugh JA, Monterrosa A, Cornell J. Minority advantage in diabetic end-stage renal disease survival on hemodialysis: due to different proportions of diabetic type? Am J Kidney Dis. 1996; 28: 226-234.
21. Hayashino Y, Fukuhara S, Akiba T, Akizawa T, Asano Y, Saito A, Bragg-Gresham JL, Ramirez SP, Port FK, Kurokawa K. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia. 2007; 50: 1170-1177.
22. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y; Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007; 18: 896-903.
23. Nagayama H, Inaba M, Okabe R, Emoto M, Ishimura E, Okazaki S, Nishizawa Y. Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother. 2009; 63: 236-240.
24. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, Calles-Escandon J, Russell GB, Freedman BI. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008; 73: 1062-1068.
25. American Diabetes Association. Mellitus TECotDaCoD. Report on the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2005; 21 (Suppl 1): S5-S22.
26. Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y, Shoji T, Ishimura E, Ohta T, Nakatani T, Kim M, Nishizawa Y. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis. 2002; 39: 1261-1269.
27. Maekawa K, Shoji T, Emoto M, Okuno S, Yamakawa T, Ishimura E, Inaba M, Nishizawa Y. Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant. 2008; 23: 2329-2336.
28. Kouzuma T, Uemastu Y, Usami T, Imamura S. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta. 2004; 346: 135-143.
29. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, Shino T, Yamada C, Nagaoka Y. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med. 1998; 37: 826-830.
30. Kumeda Y, Inaba M, Shoji S, Ishimura E, Inariba H, Yabe S, Okamura M, Nishizawa Y. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf). 2008; 69: 556-561.
31. Yamada S, Inaba M, Shidara K, Okada S, Emoto M, Ishimura E, Nishizawa Y. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci. 2008; 83: 516-519.
32. Yamada S, Inaba M, Okada S, Imanishi Y, Mori K, Emoto M, Ishimura E, Nishizawa Y. Association of glycated albumin, but not glycated hemoglobin, with calcaneus quantitative ultrasound in male hemodialysis patients with type 2 diabetes mellitus. Metabolism. 2010; 59: 390-394.
33. Ishimura E, Okuno S, Kono K, Fujino-Kato Y, Maeno Y, Kagitani S, Tsuboniwa N, Nagasue K, Maekawa K, Yamakawa T, Inaba M, Nishizawa Y. Glycemic control and survival of diabetic hemodialysis patients-importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract. 2009; 83: 320-326.
34. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007; 30: 1049-1055.
35. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287: 2563-2569.
36. American Diabetes Association. Standards of Medical Care in Diabetes - 2008. Diabetes Care. 2008; 31 (Suppl 1): S12-S54.
37. Tahara Y. Glycoalbumin [in Japanese]. Kettouti wo Miru, Kangaeru; 2000. p. 62-69.
38. Kashiwagi M, Tanaka A, Kitabata H, Tsujioka H, Matsumoto H, Arita Y, Ookochi K, Kuroi A, Kataiwa H, Tanimoto T, Ikejima H, Takarada S, Kubo T, Hirata K, Nakamura N, Mizukoshi M, Imanishi T, Akasaka T. Relationship between coronary arterial remodeling, fibrous cap thickness and highsensitivity C-reactive protein levels in patients with acute coronary syndrome. Circ J. 2009; 73: 1291-1295.
39. Sano T, Tanaka A, Namba M, Nishibori Y, Nishida Y, Kawarabayashi T, Fukuda D, Shimada K, Yoshikawa J. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation. 2003; 108: 282-285.